Halozyme Therapeutics, Inc. (HALO) announced updates on its pipeline candidates and revealed anticipated milestones for 2014.
The company expects to complete patient enrolment for the ongoing phase II study on PEGPH20, which is being developed for the treatment of patients suffering from stage IV metastatic pancreatic cancer, in the second half of 2014.
Meanwhile, another study on PEGPH20 for the treatment of solid tumor is scheduled for initiation in late 2014.
Halozyme is also working on expanding the label of Hylenex and expects to report top-line data from the ongoing CONSISTENT 1 (CONtinuous Subcutaneous Insulin infusion STudy ENrolling Type 1 Diabetes) study this quarter. The study is evaluating Hylenex as a pre-treatment in patients with type I diabetes using insulin pumps.
Topline data from a phase II study on HTI-501 (treatment of cellulite) is also expected in this quarter.
As far as collaborative products are concerned, Roche’s (RHHBY) MabThera SC (cancer) could gain EU approval this year. Moreover, a response on Baxter’s (BAX) Biologic License Application (BLA) for HyQvia (primary immunodeficiency) is expected in mid-2014.
With Halozyme slated to report top-line data from a couple of studies, we expect 2014 to be a catalyst rich year.
Halozyme carries a Zacks Rank #3 (Hold). A better-ranked stock in the same sector is Actelion Ltd. (ALIOF), which carries a Zacks Rank #1 (Strong Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment